Eris Lifesciences Ltd
Fundamental Score
Eris Lifesciences Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of ERIS across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (34.48%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Robust Profit Growth (31.23%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Consistent Growth Track Record (21.92% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Strong Cash Generation (₹1325.32 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (54.85%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Strong Institutional Confidence (FII+DII: 26.57%)
Observation: Significant professional investor participation indicates quality recognition.
Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.
Risk Factors
5 factors identified
Premium Valuation Risk (P/E: 51.82x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Weak Earnings Growth (3.65% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (3.71% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Financial Statements
Comprehensive financial data for Eris Lifesciences Ltd
About ERIS
Business Overview
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.
Company Details
Key Leadership
Corporate Events
ERIS Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Eris Lifesciences Ltd (ERIS)?
As of 12 Feb 2026, 04:51 pm IST, Eris Lifesciences Ltd (ERIS) is currently trading at ₹1510.40. The stock has a market capitalization of ₹21.54K (Cr).
Is ERIS share price Overvalued or Undervalued?
ERIS is currently trading at a P/E ratio of 51.82x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Eris Lifesciences Ltd share price?
Key factors influencing ERIS's price include its quarterly earnings growth (Sales Growth: 6.91%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Eris Lifesciences Ltd a good stock for long-term investment?
Eris Lifesciences Ltd shows a 5-year Profit Growth of 3.71% and an ROE of 12.88%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.77 before investing.
How does Eris Lifesciences Ltd compare with its industry peers?
Eris Lifesciences Ltd competes with major peers in the Pharmaceuticals. Investors should compare ERIS's P/E of 51.82x and ROE of 12.88% against the industry averages to determine its competitive standing.
What is the P/E ratio of ERIS and what does it mean?
ERIS has a P/E ratio of 51.82x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹52 for every ₹1 of annual earnings.
How is ERIS performing according to Bull Run's analysis?
ERIS has a Bull Run fundamental score of 36.4/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does ERIS belong to?
ERIS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Eris Lifesciences Ltd.
What is Return on Equity (ROE) and why is it important for ERIS?
ERIS has an ROE of 12.88%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Eris Lifesciences Ltd generates profits from shareholders' equity.
How is ERIS's debt-to-equity ratio and what does it indicate?
ERIS has a debt-to-equity ratio of 0.77, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is ERIS's dividend yield and is it a good dividend stock?
ERIS offers a dividend yield of 0.46%, which means you receive ₹0.46 annual dividend for every ₹100 invested.
How has ERIS grown over the past 5 years?
ERIS has achieved 5-year growth rates of: Sales Growth 21.92%, Profit Growth 3.71%, and EPS Growth 3.65%.
What is the promoter holding in ERIS and why does it matter?
Promoters hold 54.85% of ERIS shares, with 16.92% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is ERIS's market capitalization category?
ERIS has a market capitalization of ₹21544 crores, placing it in the Large-cap category.
How volatile is ERIS stock?
ERIS has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for ERIS?
ERIS has a 52-week high of ₹N/A and low of ₹N/A.
What is ERIS's operating profit margin trend?
ERIS has a 5-year average Operating Profit Margin (OPM) of 34.48%, indicating the company's operational efficiency.
How is ERIS's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 6.91% and YoY Profit Growth of 31.23%.
What is the institutional holding pattern in ERIS?
ERIS has FII holding of 7.21% and DII holding of 19.36%. Significant institutional holding often suggests professional confidence in the stock.